4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock Price, Quote & AI Analysis

Live FDMT stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for 4D Molecular Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for 4D Molecular Therapeutics, Inc. Common Stock (FDMT), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

FDMT
4D Molecular Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
8.730000
High
9.375000
Low
8.600000
Volume
364,650
VWAP
-
Market Cap
$451,929,763.64
52W Range
$2.24 - $12.34
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Feb 26, 2026 Q4
After Hours
EPS Estimate: $-0.7777
Revenue Estimate: $9,363,600.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

4D Molecular Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

4D Molecular Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Company Details
Market Cap
$522.79M
Shares Outstanding
57,135,100
Weighted Shares Outstanding
51,007,874
CEO
David H. Kirn
Address
5858 HORTON STREET #455, EMERYVILLE, CA, 94608
Employees
227
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

4D Molecular Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...